Tirzepatide at week two: what the science says about early results

What did @joiceaquinocreator actually say?

Honestly? Not much that can be fact-checked. The caption tells us this is her second week post-injection of "TG de 10mg" (tirzepatide 10mg), but the spoken transcript is essentially a generic outro. Phrases like "we are looking to see more or more Simun" and "stay safe for our friends" appear to be transcription artifacts from Portuguese-language content being run through an English speech-to-text engine. What we have is a creator documenting a personal tirzepatide journey on TikTok, tagging it with #moujaro (Mounjaro) and #maromba (a Brazilian term associated with bodybuilding and gym culture). That last hashtag is worth noting. It suggests this may be framed as a fitness or body composition effort, not a metabolic disease treatment. That context changes the risk conversation considerably.

Does the science back up using tirzepatide for body composition goals?

The clinical evidence for tirzepatide is genuinely strong, but it was built in specific populations. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed participants on 15mg tirzepatide lost an average of 20.9% of body weight over 72 weeks. That is a significant result. However, those participants had a BMI of 30 or above, or 27 plus a weight-related comorbidity. The trial was not designed to study tirzepatide in otherwise healthy people pursuing gym aesthetics. Tirzepatide acts as a dual GIP and GLP-1 receptor agonist, reducing appetite and slowing gastric emptying. The muscle preservation question is real and unresolved. A 2024 analysis published in Obesity raised concerns that GLP-1 class drugs may cause lean mass loss alongside fat loss, particularly without structured resistance training. The #maromba framing suggests the creator may be combining tirzepatide with a lifting program, but no details are given, and off-label use for athletic body recomposition is not supported by current evidence in healthy-weight individuals.

What did they get wrong, or right?

We cannot credit or correct specific medical claims because the transcript contains none. What we can assess is the framing. Sharing a second-week tirzepatide update with minimal context, no disclosure of prescriber involvement, and a gym-culture hashtag creates an implicit message: tirzepatide is a body transformation tool accessible to fitness-oriented people. That framing is potentially misleading for several reasons.

• Tirzepatide carries real side effect risks including nausea, vomiting, pancreatitis, and potential thyroid C-cell effects flagged in the prescribing information.
• A 10mg dose is not a starter dose. Standard titration begins at 2.5mg weekly, with increases every four weeks. Jumping to or being on 10mg by week two would be an aggressive protocol outside typical clinical guidelines.
• No mention of medical supervision, contraindications, or monitoring appears anywhere in the caption or transcript.

The creator may be under physician care, but nothing here signals that to viewers who might replicate this approach independently.

What should you actually know about tirzepatide before following along?

Tirzepatide is a Schedule V controlled substance in Brazil as of 2023, and Mounjaro is a brand-name prescription drug. Compounded tirzepatide exists in various markets but is not equivalent to brand-name Mounjaro in terms of regulatory oversight or verified dosing consistency. The FDA has explicitly stated compounded GLP-1 products are not FDA-approved and may pose safety risks. If you are watching this video and thinking about self-administering tirzepatide based on a creator's experience, that is a high-risk path. Week two at 10mg with zero clinical context shared is not a template. Side effects tend to peak during dose escalation, and gastrointestinal events severe enough to cause dehydration are documented in clinical trials. A real conversation with a licensed prescriber, including labs, weight history, and cardiovascular screening, is the appropriate starting point. Personal anecdote on TikTok, however well-intentioned, is not that.